BioLineRx Ltd. (BLRX) Given a $3.00 Price Target by Maxim Group Analysts

Maxim Group set a $3.00 price target on BioLineRx Ltd. (NASDAQ:BLRX) in a report published on Tuesday, August 8th. The firm currently has a buy rating on the biotechnology company’s stock.

BLRX has been the topic of several other reports. Zacks Investment Research raised shares of BioLineRx from a hold rating to a buy rating and set a $1.00 price target on the stock in a report on Friday, April 21st. HC Wainwright set a $4.00 price target on shares of BioLineRx and gave the stock a buy rating in a report on Tuesday, April 18th. Oppenheimer Holdings, Inc. started coverage on shares of BioLineRx in a report on Friday, August 4th. They issued an outperform rating and a $3.00 price target on the stock. Roth Capital started coverage on shares of BioLineRx in a report on Thursday, August 3rd. They set a buy rating and a $3.00 price objective on the stock. Finally, ValuEngine raised shares of BioLineRx from a sell rating to a hold rating in a report on Monday, July 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. BioLineRx currently has a consensus rating of Buy and a consensus price target of $2.59.

BioLineRx (NASDAQ:BLRX) remained flat at $1.13 during mid-day trading on Tuesday. The company had a trading volume of 337,720 shares. BioLineRx has a 1-year low of $0.80 and a 1-year high of $1.42. The company’s market cap is $108.05 million. The company’s 50-day moving average is $1.00 and its 200 day moving average is $0.98.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.05). On average, analysts expect that BioLineRx will post ($0.24) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was posted by BNB Daily and is owned by of BNB Daily. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.baseball-news-blog.com/2017/08/19/biolinerx-ltd-blrx-given-a-3-00-price-target-by-maxim-group-analysts-updated.html.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sabby Management LLC acquired a new position in BioLineRx during the first quarter worth about $3,018,000. KCG Holdings Inc. increased its position in BioLineRx by 715.9% in the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock worth $168,000 after buying an additional 153,687 shares in the last quarter. Renaissance Technologies LLC acquired a new position in BioLineRx during the first quarter worth about $126,000. Benchmark Capital Advisors increased its position in shares of BioLineRx by 227.3% in the first quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock worth $138,000 after buying an additional 100,000 shares during the period. Finally, Citadel Advisors LLC increased its position in shares of BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock worth $102,000 after buying an additional 86,481 shares during the period. Institutional investors own 34.98% of the company’s stock.

About BioLineRx

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Analyst Recommendations for BioLineRx (NASDAQ:BLRX)

Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply